No Data
No Data
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Sino Biopharm's New Indication Application for Combo Therapy Accepted in China
Sino Biopharmaceutical (01177.HK): The application for listing approval for the new indication of the combination of Bemarolizumab Injection and Anlotinib Hydrochloride Capsules for first-line treatment of advanced renal cell carcinoma has been accepted.
On August 1st, Gelon Hui announced that Sino Biopharmaceutical, which independently developed Innovative Drug Category 1 Pembrolizumab Injection combined with Innovative Drug Category 1 Anlotinib Hydrochloride Capsules, has submitted a new indication listing application to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and has been accepted, which is used for first-line treatment of advanced unresectable or metastatic renal cell carcinoma (RCC). Pembrolizumab Injection is a novel sequence innovative fully humanized Anti-PD-L1 monoclonal antibody developed by the Group, which was approved for listing by the NMPA in May 2024 and is used for
Express News | Sino Biopharmaceutical - Acceptance of New Indication Application for Marketing of Benmelstobart Injection by Nmpa
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Sino Biopharm (01177.HK) plans to hold a board of directors meeting on August 13 to approve its interim performance.
Sino Biopharm (01177.HK) announced that it will hold a board of directors meeting on Tuesday, August 13, 2024 to approve (including) the publication of unaudited interim results for the six-month period ending June 30, 2024 for the company and its subsidiaries, as well as to consider the distribution of interim dividends (if any).
No Data